Jacques Dumas is a trained chemist with over 20 years’ experience in discovery to clinical proof-of-concept in infectious diseases and oncology.
He has been Chief Scientific Officer (CSO) of Tetraphase Pharmaceuticals since July 2015, where he oversees non-clinical sciences and CMC (Chemistry, Manufacturing and Controls) activities to support the company’s product pipeline.
Jacques became CSO at Idenix Pharmaceuticals in January 2014, then Vice President at Merck following Merck’s acquisition of Idenix.
Between 2007 and 2014, Jacques held several positions at AstraZeneca, most latterly as Vice-President and Head of Strategy, Infection Innovative Medicines. In this role, he was responsible for disease area strategy and external collaborations for AstraZeneca’s small molecule Infectious Diseases Unit. Prior to AstraZeneca, Jacques worked at Bayer Healthcare for 15 years, both in Germany and in the US.
Jacques has co-authored more than 40 peer-reviewed articles and book chapters and is regularly invited to speak at scientific conferences. He is named as an inventor on over 70 patents and patent applications related to small molecule drug discovery. Jacques is also a co-inventor of two marketed drugs, Nexavar® and Stivarga®.
He received his PhD in organic chemistry from Paris VI University in 1991 and completed a Postdoctoral Fellowship at Stanford University in 1992.